Xiaoshi Zhang

ORCID: 0000-0003-3011-1134
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Genetic factors in colorectal cancer
  • Colorectal and Anal Carcinomas
  • Colorectal Cancer Treatments and Studies
  • Immune Cell Function and Interaction
  • Fluid Dynamics Simulations and Interactions
  • Viral-associated cancers and disorders
  • Immune cells in cancer
  • Brain Metastases and Treatment
  • Cancer-related molecular mechanisms research
  • Colorectal Cancer Surgical Treatments
  • Laser-Matter Interactions and Applications
  • Cutaneous lymphoproliferative disorders research
  • Nonmelanoma Skin Cancer Studies
  • Galectins and Cancer Biology
  • Ear and Head Tumors
  • Photonic Crystal and Fiber Optics
  • interferon and immune responses
  • Monoclonal and Polyclonal Antibodies Research
  • Chinese history and philosophy
  • Glioma Diagnosis and Treatment

Sun Yat-sen University
2016-2025

Sun Yat-sen University Cancer Center
2016-2025

Chongqing Medical University
2024

Dalian Medical University
2024

Second Affiliated Hospital of Chongqing Medical University
2024

Chongqing University
2024

Aerospace Information Research Institute
2021-2024

Chinese Academy of Sciences
2021-2024

Yunnan University
2024

State Key Laboratory of Oncology in South China
2015-2023

Hepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell death (PD) -1 death-ligand 1 (PD-L1) therapy these unknown because they were excluded from clinical trials immunotherapy.This retrospective cohort study involved consecutive hepatitis surface antigen (HBsAg) -positive cancer who referred to Sun Yat-sen University Cancer Center received an...

10.1186/s40425-019-0808-5 article EN cc-by Journal for ImmunoTherapy of Cancer 2019-11-21

Pembrolizumab shows robust antitumor activity and favorable safety in metastatic melanoma. KEYNOTE-151 evaluated pembrolizumab Chinese patients, who have more aggressive melanoma subtypes than other populations. patients aged ≥18 years with advanced previously treated one line of therapy received 2 mg/kg every 3 weeks for 35 cycles or until confirmed disease progression, intolerable toxicity, study withdrawal. Primary end points were objective response rate (ORR) per RECIST v1.1 by blinded...

10.1016/j.tranon.2019.02.007 article EN cc-by-nc-nd Translational Oncology 2019-04-09

T cell exhaustion is an obstacle to immunotherapy for solid tumors. An understanding of the mechanism by which cells develop this phenotype in tumors needed. Here, hypoxia, a feature tumor microenvironment, causes (TExh) inducing mitochondrial defect. Upon exposure activated with TExh are characterized fragmentation, decreased ATP production, and oxidative phosphorylation activity. The correlated downregulation fusion protein mitofusin 1 (MFN1) upregulation miR-24. Overexpression miR-24...

10.3389/fimmu.2020.01906 article EN cc-by Frontiers in Immunology 2020-08-21

Galectin-9 (Gal-9) is known to enhance the expansion of myeloid-derived suppressor cells (MDSCs) in murine models. Its contribution MDSCs human malignancies remain be investigated. We here report that Gal-9 expression nasopharyngeal carcinoma (NPC) enhances generation (CD33+CD11b+HLA-DR-) from CD33+ bystander cells. The underlying mechanisms involve both intracellular and secreted Gal-9. Inside cells, up-regulates a variety pro-inflammatory cytokines which are critical for MDSC...

10.1038/s41389-020-00248-0 article EN cc-by Oncogenesis 2020-07-06

Background Stimulator of interferon genes (STING) is an innate immune sensor cytoplasmic double-stranded DNA originating from microorganisms and host cells. The activation cytosolic DNA-STING pathway in tumor microenvironments usually linked to more robust adaptive responses tumors, however the intracellular function STING regulatory T cells largely unknown. In present study, we aimed explore contribution cell induction (iTreg) cervical cancer (CC) microenvironments. Methods Blood samples...

10.1136/jitc-2022-005151 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2022-09-01

Background: Our study aimed to evaluate the efficacy and feasibility of neoadjuvant anti–PD-1 treatment for localized mismatch repair–deficient (dMMR) colorectal cancer (CRC). Patients Methods: The cohort included patients with dMMR CRC who received PD-1 inhibitors as therapy from 3 medical centers in Southern China. Main eligibility criteria age between 18 75 years, ECOG performance status 0 or 1, receipt ≥2 doses inhibitors. Results: A total 73 were included. Most tumors locally advanced,...

10.6004/jnccn.2022.7060 article EN Journal of the National Comprehensive Cancer Network 2023-01-01

Malignant melanoma is one of the most common malignancies. Its incidence grows rapidly at an annual rate 3−5%. Although remains low in China, it has increased rapidly, with approximately 20,000 new cases reported each year. The mortality also been increasing rapidly; contrast, although western countries, its basically unchanged and does not rise along escalation prevalence. Thus, there still a wide gap between China Western countries diagnosis treatment melanoma. Melanoma become diseases...

10.21037/cco.2015.12.02 article EN Chinese Clinical Oncology 2016-05-10

BACKGROUND. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in metastatic cancers such as melanoma and cervical cancer (CC). Here, we explored the safety, feasibility, preliminary tumor response performed translational investigations of adjuvant immunotherapy using infusion autogenous TILs (auto-TILs) following concurrent chemoradiotherapy (CCRT) patients CC who had locally advanced disease.

10.1172/jci157726 article EN cc-by Journal of Clinical Investigation 2022-06-23

Programmed cell death ligand 1 (PD-L1) is an immune checkpoint protein frequently expressed in human cancers that contributes to evasion through its binding PD-1 on activated T cells. Unveiling the mechanisms underlying PD-L1 expression essential for understanding impact of immunosuppressive microenvironment and also crucial purpose reboosting antitumor immunity. However, how regulated, particularly at translational levels, remains largely unknown. Here, we discovered a long noncoding RNA...

10.1172/jci162951 article EN cc-by Journal of Clinical Investigation 2023-04-04

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignancy with high prevalence in Southern Chinese. In order to assess whether defects of EBV-specific immunity may contribute the tumor, phenotype and function circulating T-cells tumor infiltrating lymphocytes (TILs) were investigated untreated NPC patients. Circulating naïve CD3+CD45RA+ CD4+CD25- cells decreased, while activated CD4+CD25+ CD3-CD16+ NK-cells increased patients compared healthy donors. The frequency...

10.1371/journal.pone.0001122 article EN cc-by PLoS ONE 2007-11-06

The effect of polycomb chromobox (Cbx) proteins in cancer is context-dependent. Chromobox homolog 8 (CBX8) was originally characterized as a transcriptional repressor, which inhibits cell proliferation Ink4a-Arf-dependent and -independent manner. However, the role CBX8 colorectal remains unknown. Here, we found that high expression associated with low rate distant metastasis good prognosis CRC patients, even though up-regulated lines clinical samples. Knockdown inhibited vitro vivo, mostly...

10.18632/oncotarget.2502 article EN Oncotarget 2014-10-24

β2-microglobulin (B2M) and Janus kinases 1 2 (JAK1/2) mutations have been suggested as genetic mechanisms of immune evasion for anti-programmed cell death protein (PD-1) therapy. Whether B2M JAK1/2 lose-of-function mutation can cause primary resistance to anti-PD-1 therapy in colorectal carcinoma (CRC) patients remains controversial. Here, we sought compare the efficacy DNA mismatch repair deficient/microsatellite instability-high CRC with or without mutations. Thirty-Five who received were...

10.1097/cji.0000000000000417 article EN cc-by-nc-nd Journal of Immunotherapy 2022-03-28

Colorectal cancer with mismatch repair deficiency is usually less aggressive and associated a lower risk of distant metastasis. Immune checkpoint inhibition, rather than traditional chemoradiotherapy, has shown great advantages in treating such patients.This study aimed to verify the hypothesis that locally very advanced (T4b) colorectal without metastases might present higher probability be more sensitive neoadjuvant immune inhibition.This was designed as single-center retrospective...

10.1097/dcr.0000000000002466 article ES Diseases of the Colon & Rectum 2022-04-29

Stimulator of interferon genes (STING) agonists have been developed and tested in clinical trials for their antitumor activity. However, the specific cell population(s) responsible such STING activation-induced immunity not completely understood. In this study, we demonstrated that endothelial expression was critical agonist-induced activation endothelium promoted vessel normalization CD8+ T infiltration - which required type I IFN (IFN-I) signaling- but IFN-γ or CD4+ cells. Rather than an...

10.1172/jci180622 article EN cc-by Journal of Clinical Investigation 2025-01-15

Abstract Background One of the putative mechanisms tumor immune escape is based on hypothesis that carcinomas actively create an immunosuppressed state via expression indoleamine 2,3-dioxygenase (IDO), both in cancer cells and among tumor-draining lymph nodes (TDLN). In attempt to verify this hypothesis, patterns IDO colon cancers were examined. Methods Seventy-one cases pathologically-confirmed tissues matched with adjacent non-cancerous tissues, node metastases, TDLN without metastases...

10.1186/1479-5876-7-71 article EN cc-by Journal of Translational Medicine 2009-08-20

Routine chemotherapy often cannot achieve good therapeutic effects because of multidrug resistance (MDR). MDR is frequently caused by the elevated expression MDR1 gene encoding P-glycoprotein (P-gp). E2F1 a overexpressed protein in human tumor cells that increases activity promoter, resulting higher P-gp levels. The upregulation might contribute to survival during chemotherapy. confers anticancer drug resistance; however, we speculate whether affects through other pathways. This study...

10.1186/1471-2407-14-904 article EN cc-by BMC Cancer 2014-12-01

10.1016/j.cam.2016.04.020 article EN publisher-specific-oa Journal of Computational and Applied Mathematics 2016-05-01

The presence of liver metastasis correlates with poor therapeutic response PD-1 blockade therapy in melanoma. A novel treatment protocol by combining cryoablation transarterial infusion pembrolizumab (CATAP) was proposed, and its feasibility safety assessed among this group patients.This registered ambispective cohort study enrolled fifteen melanoma patients multiple hepatic metastases who received planned two-stage CATAP therapy: the combined stage, subtotal on day 1, which one to two...

10.1007/s00262-020-02566-z article EN cc-by Cancer Immunology Immunotherapy 2020-04-24

Survival is generally poor for Chinese patients with advanced melanoma because of high rates acral and mucosal limited therapeutic options. The first analysis the phase 1b KEYNOTE-151 study showed second-line pembrolizumab was well tolerated had clinically meaningful antitumor activity in melanoma. Three-year follow-up presented. Eligible were descent unresectable stage III/IV that progressed after first-line therapy. Patients received 2 mg/kg every 3 weeks ≤35 cycles. Primary end points...

10.3389/fimmu.2022.882471 article EN cc-by Frontiers in Immunology 2022-10-11
Coming Soon ...